Last reviewed · How we verify
Multipotent Stromal Cells
At a glance
| Generic name | Multipotent Stromal Cells |
|---|---|
| Sponsor | AlloCure Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines (PHASE1)
- Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression (PHASE1)
- Autologous Stem Cell Study for Adult TBI (Phase 2b) (PHASE2)
- Evaluation of Clinical Efficacy of Autologous Adipose Tissue Derived ADSCSs in Treatment of Osteoarthritis (OA) (PHASE1, PHASE2)
- Adipose Tissue Derived Stromal Vascular Fraction (SVF) Application in Treatment of Long Bones Nonunion (PHASE1, PHASE2)
- Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines (PHASE1)
- Human Umbilical Cord Stroma MSC in Myocardial Infarction (PHASE1, PHASE2)
- Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multipotent Stromal Cells CI brief — competitive landscape report
- Multipotent Stromal Cells updates RSS · CI watch RSS
- AlloCure Inc. portfolio CI